| # | Title | Journal | Year | Citations |
|---|
| 1 | JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan | Liver Cancer | 2014 | 512 |
| 2 | Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition) | Liver Cancer | 2020 | 427 |
| 3 | Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition) | Liver Cancer | 2018 | 426 |
| 4 | Management of Hepatocellular Carcinoma in Japan: JSH Consensus Statements and Recommendations 2021 Update | Liver Cancer | 2021 | 307 |
| 5 | Treatment of Hepatocellular Carcinoma: A Systematic Review | Liver Cancer | 2012 | 268 |
| 6 | Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function | Liver Cancer | 2017 | 202 |
| 7 | A Radiomics Nomogram for Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma | Liver Cancer | 2019 | 201 |
| 8 | From Cirrhosis to Hepatocellular Carcinoma: New Molecular Insights on Inflammation and Cellular Senescence | Liver Cancer | 2013 | 175 |
| 9 | Surveillance, Diagnosis, Treatment, and Outcome of Liver Cancer in Japan | Liver Cancer | 2015 | 175 |
| 10 | Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma | Liver Cancer | 2015 | 172 |
| 11 | A Changing Paradigm for the Treatment of Intermediate-Stage Hepatocellular Carcinoma: Asia-Pacific Primary Liver Cancer Expert Consensus Statements | Liver Cancer | 2020 | 172 |
| 12 | Emerging Signaling Pathways in Hepatocellular Carcinoma | Liver Cancer | 2012 | 169 |
| 13 | Hepatic Iron Overload and Hepatocellular Carcinoma | Liver Cancer | 2014 | 160 |
| 14 | Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications | Liver Cancer | 2017 | 159 |
| 15 | Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis | Liver Cancer | 2019 | 159 |
| 16 | Surgical and Locoregional Therapy of HCC: TACE | Liver Cancer | 2015 | 154 |
| 17 | Molecular Biology of Liver Cancer Stem Cells | Liver Cancer | 2014 | 146 |
| 18 | Epidemiology and Surveillance of Hepatocellular Carcinoma | Liver Cancer | 2012 | 144 |
| 19 | Association between Loss of Skeletal Muscle Mass and Mortality and Tumor Recurrence in Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis | Liver Cancer | 2018 | 135 |
| 20 | Tumor Markers for Hepatocellular Carcinoma: Simple and Significant Predictors of Outcome in Patients with HCC | Liver Cancer | 2015 | 125 |
| 21 | Survival Analysis over 28 Years of 173,378 Patients with Hepatocellular Carcinoma in Japan | Liver Cancer | 2016 | 122 |
| 22 | How to Define Transarterial Chemoembolization Failure or Refractoriness: A European Perspective | Liver Cancer | 2014 | 118 |
| 23 | Liver Resection and Transplantation in Hepatocellular Carcinoma | Liver Cancer | 2012 | 113 |
| 24 | Tumor Heterogeneity in Hepatocellular Carcinoma: Facing the Challenges | Liver Cancer | 2016 | 108 |
| 25 | Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations | Liver Cancer | 2021 | 108 |
| 26 | A New Treatment Option for Intermediate-Stage Hepatocellular Carcinoma with High Tumor Burden: Initial Lenvatinib Therapy with Subsequent Selective TACE | Liver Cancer | 2019 | 107 |
| 27 | Treatment of Advanced Hepatocellular Carcinoma with Emphasis on Hepatic Arterial Infusion Chemotherapy and Molecular Targeted Therapy | Liver Cancer | 2012 | 103 |
| 28 | Recent Advances in Tumor Ablation for Hepatocellular Carcinoma | Liver Cancer | 2015 | 97 |
| 29 | Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment | Liver Cancer | 2017 | 97 |
| 30 | The Burden and Trends of Primary Liver Cancer Caused by Specific Etiologies from 1990 to 2017 at the Global, Regional, National, Age, and Sex Level Results from the Global Burden of Disease Study 2017 | Liver Cancer | 2020 | 97 |
| 31 | Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma | Liver Cancer | 2020 | 96 |
| 32 | Patient Selection for Transarterial Chemoembolization in Hepatocellular Carcinoma: Importance of Benefit/Risk Assessment | Liver Cancer | 2018 | 95 |
| 33 | Current Status of Hepatic Arterial Infusion Chemotherapy | Liver Cancer | 2015 | 93 |
| 34 | Chinese Expert Consensus on Multidisciplinary Diagnosis and Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus (2018 Edition) | Liver Cancer | 2020 | 93 |
| 35 | Diagnosis of Pathologically Early HCC with EOB-MRI: Experiences and Current Consensus | Liver Cancer | 2014 | 92 |
| 36 | Biomarkers: Evaluation of Screening for and Early Diagnosis of Hepatocellular Carcinoma in Japan and China | Liver Cancer | 2013 | 90 |
| 37 | Image-Guided Ablation of Malignant Liver Tumors: Recommendations for Clinical Validation of Novel Thermal and Non-Thermal Technologies - A Western Perspective | Liver Cancer | 2015 | 90 |
| 38 | Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma | Liver Cancer | 2018 | 89 |
| 39 | Systemic Treatment Options in Hepatocellular Carcinoma | Liver Cancer | 2019 | 89 |
| 40 | Newly Proposed ALBI Grade and ALBI-T Score as Tools for Assessment of Hepatic Function and Prognosis in Hepatocellular Carcinoma Patients | Liver Cancer | 2019 | 88 |
| 41 | Clinical Practice Guidelines for Hepatocellular Carcinoma Differ between Japan, United States, and Europe | Liver Cancer | 2015 | 83 |
| 42 | Surgery for Intermediate and Advanced Hepatocellular Carcinoma: A Consensus Report from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014) | Liver Cancer | 2016 | 83 |
| 43 | Systemic Treatment for Advanced Hepatocellular Carcinoma | Liver Cancer | 2019 | 82 |
| 44 | Preoperative Visceral Adiposity and Muscularity Predict Poor Outcomes after Hepatectomy for Hepatocellular Carcinoma | Liver Cancer | 2019 | 80 |
| 45 | Local Ablation for Hepatocellular Carcinoma in Taiwan | Liver Cancer | 2013 | 79 |
| 46 | A Worldwide Survey of the Current Daily Practice in Liver Surgery | Liver Cancer | 2013 | 79 |
| 47 | Chemoembolization in Patients with Hepatocellular Carcinoma | Liver Cancer | 2012 | 78 |
| 48 | Comparison of International Guidelines for Noninvasive Diagnosis of Hepatocellular Carcinoma | Liver Cancer | 2012 | 78 |
| 49 | Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update | Liver Cancer | 2020 | 78 |
| 50 | Insufficient Ablative Margin Determined by Early Computed Tomography May Predict the Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation | Liver Cancer | 2015 | 77 |
